BL M02D1
Alternative Names: BL-M02D1; BL-M02D1-ADCLatest Information Update: 28 Nov 2025
At a glance
- Originator Sichuan Baili Pharmaceutical; SystImmune
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action TROP2 antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer; Non-small cell lung cancer
Highest Development Phases
- Phase II Lung cancer; Triple negative breast cancer
- Phase I/II Non-small cell lung cancer; Solid tumours
- Phase I Breast cancer
- No development reported Gastrointestinal cancer
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in China (Parenteral)
- 28 Nov 2025 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
- 28 Nov 2025 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in USA (IV, Infusion)